Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Eikon Therapeutics, Inc. (EIKN) had Consolidated Net Income/Loss of -324.25M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-324.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-324.25M |
|
|
Consolidated Net Income/Loss |
-324.25M |
-- |
|
-- |
|
-- |
|
2.81M |
|
2.81M |
|
-115.29 |
|
-115.29 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|